Tuesday, July 23, 2019
Repeated Use Of Allogeneic Umbilical Cord Blood Mesenchymal Cells For Treatment Of Equine Superficial Digital Flexor Tendonitis
Research team: Judith Koenig, Nathalie Cote, Thomas Koch, Stephanie Nykamp
Graduate Student & LA Surgery Resident: Alejandro Merchan
The repeated use of allogeneic CB-MSC for treatment of naturally occurring superficial digital flexor tendinitis in horses utilizing intralesional administration is safe and promotes better quality faster healing than repeated PRP treatment.
We are looking for: Thoroughbred race horses in training and racing between 2 and 6 years old. Horses must have been diagnosed with front limb superficial digital flexor tendinitis (SDFT) within the first 4 weeks of the injury. To meet inclusion criteria horses must have injured a minimum of 50% cross sectional area of the SDFT and have a hypoechoic defect within the tendon on images.
If you have a case like that and the owner/trainer is interested to participate in the study please contact either Dr Judith Koenig firstname.lastname@example.org or Dr Nathalie Cote email@example.com for further details.
We appreciate your support in finding cases to participate in the study to help us identify the best treatment for tendonitis in horses!
Alejandro, Judith, Nathalie, Thomas and Stephanie